Clinical Trials

May 11, 2011

A Study to Evaluate Efficacy and Safety of Oral Bay 63-2521 in Patients With CTEPH

  • Study Sponsor: Bayer Healthcare Pharmaceuticals
  • Start Date: 2/2009
  • End Date: 11/2012
  • Design: Placebo-controlled
  • Age range (years): from 18 to 80
  • Type of PH
    • CTEPH (Group 4)
  • Study Duration for individual patient: 16 weeks
  • Bayer study listing
  • Listing on


FacebookTwitterInstagram iconLinkedInYouTube

For optimal viewing of, please use a standards-compliant browser such as Google Chrome or Firefox.

The information provided on the PHA website is provided for general information only. It is not intended as legal, medical or other professional advice, and should not be relied upon as a substitute for consultations with qualified professionals who are familiar with your individual needs. PHA does not endorse or recommend any commercial products or services.

801 Roeder Road, Ste. 1000, Silver Spring, MD 20910   Patient-to-Patient Support Line: 1-800-748-7274
    Privacy Policy    Provide Feedback & Report Bugs

Designed by Matrix Group International, Inc.® | © 2016 Pulmonary Hypertension Association. All Rights Reserved.


The National Organization for Rare Disorders (NORD) awarded PHA the Abbey S. Meyers Leadership Award in 2012 for outstanding service to PHA members in advocacy, education and other key areas.


Read the Advances in PH journal, take free CME/CEU courses, access presentations from major PH conferences, locate a medical education event near you and more.

Visit PHA Online University